Advances in adjuvant therapy for operable N2 non-small cell lung cancer: a narrative review
Non-small cell lung cancer (NSCLC) is still the disease with the highest incidence rate among malignant tumors, in which NSCLC under N2 stage has obvious survival differences among different patients due to its high heterogeneity. For NSCLC under this stage, the current treatment options are: preope...
Saved in:
Main Authors: | Lei Liu, Yilong Mao, Leilei Guo, Chencong Li, Yiqian Wang |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2025-01-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2024.1523743/full |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Postoperative radiotherapy improves survival in completely resected non-small cell lung cancer with pathologic N2 stage IIIA and positive lymph node count greater than one: a SEER-based retrospective cohort study
by: Diyang Zhu, et al.
Published: (2025-02-01) -
Effects of respiratory sarcopenia on the postoperative course in elderly lung cancer patient: a retrospective study
by: Dong Jae Han, et al.
Published: (2025-01-01) -
Postoperative brachytherapy alone for 217 patients with early-stage oral cavity squamous cell carcinoma
by: C. Schweizer, et al.
Published: (2025-03-01) -
Dexmedetomidine versus Dexamethasone as Perineural Adjuvants in Supraclavicular Brachial Plexus Block: An Interventional Study
by: Charmi Hitenbhai Shah, et al.
Published: (2025-02-01) -
Clinical Benefits of Parasternal Block with Multihole Catheters when Inserted before Sternotomy
by: Vedat Eljezi, et al.
Published: (2025-01-01)